Recombinant NKG2A (Monalizumab Biosimilar) antibody

Catalog No. ABIN7538069

This Humanized Monoclonal antibody specifically detects NKG2A (Monalizumab Biosimilar) in ELISA and WB. It exhibits reactivity toward Human.

Quick Overview for Recombinant NKG2A (Monalizumab Biosimilar) antibody (ABIN7538069)

Target: NKG2A (Monalizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This NKG2A (Monalizumab Biosimilar) antibody is un-conjugated

Application: ELISA, Western Blotting (WB)

Grade: Research Grade

Product Details anti-NKG2A (Monalizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Monalizumab Biosimilar - Anti-KLRC1, NKG2A, CD159a, CD94 mAb - Research Grade

Characteristics: Antibody Type: IgG4-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Purity: > 85%

Isotype: IgG4

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS buffer PH7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for NKG2A (Monalizumab Biosimilar)

Target: NKG2A (Monalizumab Biosimilar)

Background: Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

CAS-No: 1228763-95-8